Wayne Kuznar

Articles

Nivolumab Improves Survival in Advanced Esophageal Cancer

October 1st 2019

Nivolumab extended overall survival compared with chemotherapy in patients with previously treated advanced esophageal squamous cell carcinoma.

Case Series Highlights Afatinib Activity in NRG1+ Cancers

September 30th 2019

A case series presented at the 2019 ESMO Congress highlighted the activity of afatinib in patients with NRG1-positive tumors.

PD-L1 Assays Demonstrate

September 29th 2019

An exploratory biomarker substudy of Impassion130 demonstrated clinical activity of atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane) in a subgroup of patients with triple-negative breast cancer who had immune cell PD-L1 expression by the SP142 immunohistochemistry assay, regardless of the site of the tumor sample.

Atezolizumab Combo Confirmed as Frontline Standard in Advanced Small Cell Lung Cancer

September 29th 2019

With follow-up of nearly 2 years, the addition of atezolizumab to first-line carboplatin plus etoposide for the treatment of extensive stage small cell lung cancer continues to demonstrate improved overall survival compared with placebo plus CP/ET.

Adding Atezolizumab May Improve Outcomes in HER2+ Breast Cancer With PD-L1 Expression

September 28th 2019

A numerical improvement in overall survival was realized with the addition of atezolizumab (Tecentriq) to ado-trastuzumab emtansine (T-DM1; Kadcyla) compared with T-DM1 alone.

Telaglenastat Plus Everolimus Emerges as Novel Approach in Metastatic RCC

September 28th 2019

Adding the investigational glutaminase inhibitor telaglenastat to everolimus extends progression-free survival compared with everolimus alone in patients with heavily pretreated advanced renal cell carcinoma.

Atezolizumab Improves Survival in High PD-L1 Expressing NSCLC

September 27th 2019

Atezolizumab (Tecentriq) monotherapy improved overall survival compared with platinum-based chemotherapy as a first-line treatment of certain patients with wild-type non–small cell lung cancer.

Pemigatinib Active as Second-Line Treatment for FGFR2+ Cholangiocarcinoma

September 27th 2019

More than one-third of patients with previously treated locally advanced or metastatic cholangiocarcinoma with an FGFR2 rearrangement or fusion had durable objective responses to treatment with pemigatinib.

Nivolumab/Ipilimumab Combo Leads to Durable Responses in Metastatic Melanoma With Asymptomatic Brain Mets

June 13th 2019

The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) led to durable intracranial responses in patients with metastatic melanoma and asymptomatic brain metastases.

Second Relapse Common After Initial Melanoma Recurrence on Adjuvant PD-1 Inhibition

June 13th 2019

Despite local therapy, many patients with locoregional recurrence of melanoma during or after adjuvant anti–PD-1 therapy relapse again.

Continued Survival Benefits Observed With Encorafenib/Binimetinib Combo in Advanced Melanoma

June 12th 2019

Updated results from the phase III COLUMBUS trial show continued prolonged progression-free and overall survival with the combination of encorafenib and binimetinib compared with BRAF inhibition alone in patients with advanced/metastatic BRAF V600-mutant melanoma.

Larotrectinib Effective in TRK+ Pediatric Cancers and CNS Tumors

June 7th 2019

The efficacy of larotrectinib is supported in distinct patient populations with TRK fusion cancer—specifically pediatric patients and adult or pediatric patients with brain metastases or primary central nervous system tumors.

Capivasertib Combined With Fulvestrant Improves PFS in ER+ Breast Cancer

June 5th 2019

Adding the Akt inhibitor capivasertib to fulvestrant led to a more than doubling of progression-free survival compared with fulvestrant alone in patients with endocrine-resistant estrogen receptor-positive advanced breast cancer.

Margetuximab Superior to Trastuzumab on PFS in HER2-Positive Metastatic Breast Cancer Carriers of CD16A-F Allele

June 5th 2019

Margetuximab, a novel Fc-engineered HER2-targeted antibody, improved progression-free survival compared with trastuzumab in patients with pretreated HER2-positive metastatic breast cancer in the open-label phase III SOPHIA clinical trial.

PD-1 Inhibitor Spartalizumab Plus Dabrafenib/Trametinib Active in BRAF+ Melanoma

June 5th 2019

The triplet of the PD-1 inhibitor spartalizumab, dabrafenib, and trametinib led to a complete response in more than 40% of patients with previously untreated advanced BRAF V600–mutant melanoma.

High TMB Metastatic Breast Cancer Responds to Pembrolizumab Monotherapy

June 2nd 2019

Examination of a cohort of patients with metastatic breast cancer and high mutational burden who were enrolled in the phase II Targeted Agent and Profiling Utilization Registry basket study shows that pembrolizumab monotherapy has antitumor activity in this population of heavily pretreated patients.

Cemiplimab Has Potent Activity in Locally Advanced Cutaneous Squamous Cell Carcinoma

June 2nd 2019

Among patients with locally advanced cutaneous squamous cell carcinoma (CSCC) who were enrolled in the pivotal EMPOWER-CSCC-1 phase II study, cemiplimab exhibited substantial antitumor activity and induced durable responses similar to those experienced in patients with metastatic CSCC who were enrolled in the same study.

Novel CAR Therapy Shows Promising Early Signals in Pancreatic Cancer

March 31st 2019

Although CAR T-cell therapy has not yet proved effective against solid tumors, a novel CAR that targets mesothelin proteins expressed in pancreatic cancer is showing early signs of activity.

Tumor Mutational Burden Poses Challenges as Immunotherapy Biomarker

March 29th 2019

Although TMB is associated with responses to checkpoint inhibitor therapy, more research is needed to better understand how TMB interacts with other genomic correlates of the immune cycle before the biomarker can be incorporated into clinical practice.

PARP Inhibition Strategies Refined in Ovarian Cancer Guidelines

March 24th 2019

An updated guideline (version 1.2019) from the NCCN for the management of ovarian cancer recommends specific PARP inhibitors for the treatment of recurrent disease, describes patient selection criteria for each agent, and establishes criteria for PARP inhibitor maintenance therapy.